Treatment of dysmyelopoietic/leukemic syndromes with myelofibrosis and megakaryocytic hyperplasia with large doses of cytosine arabinoside.
Eight patients with inaspiratable bone marrows due to significant degrees of fibrosis were treated with high dose cytosine arabinoside because of either documented or suspected coexistent acute leukemia. The peripheral blood counts returned to normal in 7 patients. Remissions were short lived and bone marrow abnormalities persisted suggesting that consolidation therapy should be administered to these patients as soon as their peripheral blood counts are normalized.
D000208:Acute Disease; D000328:Adult; D000368:Aged; D001706:Biopsy; D001772:Blood Cell Count; D001853:Bone Marrow / Q000473:pathology; D003561:Cytarabine / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D006965:Hyperplasia; D007938:Leukemia / Q000188:drug therapy*; D008297:Male; D008533:Megakaryocytes / Q000187:drug effects; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy*; D010198:Pancytopenia / Q000188:drug therapy; D055728:Primary Myelofibrosis / Q000188:drug therapy*; D013920:Thrombocythemia, Essential / Q000188:drug therapy
D003561:Cytarabine